Macrolide antibiotic binding to the ribosome inhibits catalysis of peptide bond formation between specific donor and acceptor substrates. Why particular reactions are problematic for the macrolide-bound ribosome remains unclear. Using comprehensive mutational analysis and biochemical experiments with synthetic substrate analogs, we find that the positive charge of these specific residues and the length of their side chains underlie inefficient peptide bond formation in the macrolide-bound ribosome. Even in the absence of antibiotic, peptide bond formation between these particular donors and acceptors is rather inefficient, suggesting that macrolides magnify a problem present for intrinsically difficult substrates. Our findings emphasize the...
AbstractThe atomic structures of the large ribosomal subunit from Haloarcula marismortui and its com...
SummaryThe traditional view of macrolide antibiotics as plugs inside the ribosomal nascent peptide e...
Erythromycin, the first antibacterial macrolide introduced into the clinical setting over 50 years a...
Macrolides are clinically important antibiotics thought to inhibit bacterial growth by impeding the ...
Macrolides are a large group of clinically relevant antibiotics that inhibit protein synthesis by bi...
Protein synthesis is catalysed by ribosomes and cytoplasmic factors. Bacterial ribosomes (70S) are m...
Bacterial antibiotic resistance can occur by many mechanisms. An intriguing class of mutants is resi...
Ketolides represent the latest group of macrolide antibiotics. Tight binding of ketolides to the rib...
SummaryAccumulating evidence suggests that, during translation, nascent chains can form specific int...
Glycosylation of macrolide antibiotics confers host cell immunity from endogenous and exogenous agen...
Macrolide antibiotics are thought to clog up the ribosomal tunnel and thereby block general protein ...
AbstractPeptide bond formation and peptide release are catalyzed in the active site of the large sub...
Macrolide antibiotics bind in the nascent peptide exit tunnel of the bacterial ribosome and prevent ...
SummaryThe polypeptide exit tunnel is an important functional compartment of the ribosome where the ...
Many antibiotics inhibit bacterial growth by binding to the ribosome and interfering with protein bi...
AbstractThe atomic structures of the large ribosomal subunit from Haloarcula marismortui and its com...
SummaryThe traditional view of macrolide antibiotics as plugs inside the ribosomal nascent peptide e...
Erythromycin, the first antibacterial macrolide introduced into the clinical setting over 50 years a...
Macrolides are clinically important antibiotics thought to inhibit bacterial growth by impeding the ...
Macrolides are a large group of clinically relevant antibiotics that inhibit protein synthesis by bi...
Protein synthesis is catalysed by ribosomes and cytoplasmic factors. Bacterial ribosomes (70S) are m...
Bacterial antibiotic resistance can occur by many mechanisms. An intriguing class of mutants is resi...
Ketolides represent the latest group of macrolide antibiotics. Tight binding of ketolides to the rib...
SummaryAccumulating evidence suggests that, during translation, nascent chains can form specific int...
Glycosylation of macrolide antibiotics confers host cell immunity from endogenous and exogenous agen...
Macrolide antibiotics are thought to clog up the ribosomal tunnel and thereby block general protein ...
AbstractPeptide bond formation and peptide release are catalyzed in the active site of the large sub...
Macrolide antibiotics bind in the nascent peptide exit tunnel of the bacterial ribosome and prevent ...
SummaryThe polypeptide exit tunnel is an important functional compartment of the ribosome where the ...
Many antibiotics inhibit bacterial growth by binding to the ribosome and interfering with protein bi...
AbstractThe atomic structures of the large ribosomal subunit from Haloarcula marismortui and its com...
SummaryThe traditional view of macrolide antibiotics as plugs inside the ribosomal nascent peptide e...
Erythromycin, the first antibacterial macrolide introduced into the clinical setting over 50 years a...